We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| NeuroMetrix Inc | NASDAQ:NUROW | NASDAQ | Equity Warrant |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.142 | 0.003 | 0.30 | 0 | 01:00:00 |
From Jun 2019 to Jun 2024
NeuroMetrix, Inc. (Nasdaq:NURO) today announced it will be a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 10-12, 2017, at Lotte New York Palace Hotel in New York City. Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
The NeuroMetrix presentation is scheduled for Monday, September 11, 2017 at 11:15 AM Eastern time. A live audio webcast will be available on the investor relations section of the corporate website, www.NeuroMetrix.com. This webcast will be archived after the live event.
About NeuroMetrix
NeuroMetrix is a commercial stage, innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell®, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170905006012/en/
NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761SVP and Chief Financial OfficerNeurometrix.ir@neurometrix.com
1 Year NeuroMetrix Chart |
1 Month NeuroMetrix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
